VivoSeq
Other

HER2

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

HER2 is an early-stage landscape with 0 programs across 2 companies. The most active players are SciClone Pharmaceuticals, Vironexis Biotherapeutics Inc..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SciClone Pharmaceuticals

0 programs

PreclinicalV

Vironexis Biotherapeutics Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Recruiting3 · 33%
Completed2 · 22%
Unknown status2 · 22%
Active, not recruiting1 · 11%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

TRUDI: TDXD+Durva in HER2+/Low IBC
Recruiting·FFilipa Lynce, MD·Phase 2·NCT05795101·63 enrolled
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
Recruiting·SSciClone Pharmaceuticals·N/A·NCT06544577·350 enrolled
A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer
Recruiting·VVironexis Biotherapeutics Inc.·Preclinical·NCT07192432·27 enrolled
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Active, not recruiting·—·Phase 2·NCT02326974·164 enrolled
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Completed·—·Phase 1·NCT01109095·16 enrolled
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02152943·37 enrolled
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Withdrawn·NNuvation Bio Inc.·Phase 1/2·NCT05191004
Clinical Study of 68Ga Labeled HER2 Affibody Analogues
Unknown status·XXijing Hospital·Phase 1·NCT05411432·56 enrolled
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05969184·94 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)